PMID- 31221807
OWN - NLM
STAT- MEDLINE
DCOM- 20200715
LR  - 20210317
IS  - 1399-3003 (Electronic)
IS  - 0903-1936 (Linking)
VI  - 54
IP  - 3
DP  - 2019 Sep
TI  - King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum 
      clinically important difference.
LID - 1900281 [pii]
LID - 10.1183/13993003.00281-2019 [doi]
AB  - Health status is increasingly used in clinical practice to quantify symptom 
      burden and as a clinical trial end-point in patients with interstitial lung 
      disease (ILD). The King's Brief Interstitial Lung Disease (KBILD) questionnaire 
      is a brief, validated 15-item, disease-specific, health-related quality of life 
      questionnaire that is increasingly used in clinical trials, but little data exist 
      regarding the minimum clinically important difference (MCID). Using pulmonary 
      rehabilitation as a model, we aimed to determine the responsiveness of KBILD and 
      provide estimates of the MCID.KBILD scores, Chronic Respiratory Questionnaire 
      (CRQ) scores, Medical Research Council (MRC) Dyspnoea score and incremental 
      shuttle walk test (ISWT) distance were measured in 209 patients with ILD (105 
      with idiopathic pulmonary fibrosis (IPF)) before and after an outpatient 
      pulmonary rehabilitation programme. Changes with intervention and Cohen's effect 
      size were calculated. Anchor-based (linear regression and receiver operating 
      characteristic plots) or distribution-based approaches (0.5 sd and standard error 
      of measurement) were used to estimate the MCID of KBILD domain and total 
      scores.KBILD, CRQ, MRC Dyspnoea and ISWT improved with intervention, and the 
      effect sizes of KBILD domain and total scores ranged from 0.28 to 0.38. Using 
      anchor-based estimates, the MCID estimates for KBILD-Psychological, 
      KBILD-Breathlessness and activities, and KBILD-Total were 5.4, 4.4 and 
      3.9 points, respectively. Using distribution-based methods, the MCID estimate for 
      KBILD-Chest symptoms was 9.8 points. The MCID estimates for KBILD in IPF patients 
      were similar.In patients with ILD and IPF, KBILD is responsive to intervention 
      with an estimated MCID of 3.9 points for the total score.
CI  - Copyright (c)ERS 2019.
FAU - Nolan, Claire M
AU  - Nolan CM
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK c.nolan@rbht.nhs.uk.
AD  - Harefield Pulmonary Rehabilitation Unit, Royal Brompton and Harefield NHS 
      Foundation Trust, Harefield, UK.
FAU - Birring, Surinder S
AU  - Birring SS
AD  - Centre for Human and Applied Physiological Sciences, School of Basic and Medical 
      Biosciences, Faculty of Life Sciences and Medicine, King's College London, 
      London, UK.
FAU - Maddocks, Matthew
AU  - Maddocks M
AD  - Division of Palliative Care, Policy and Rehabilitation, Cicely Saunders 
      Institute, King's College London, London, UK.
FAU - Maher, Toby M
AU  - Maher TM
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation 
      Trust, London, UK.
FAU - Patel, Suhani
AU  - Patel S
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
FAU - Barker, Ruth E
AU  - Barker RE
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Jones, Sarah E
AU  - Jones SE
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
FAU - Walsh, Jessica A
AU  - Walsh JA
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
AD  - Harefield Pulmonary Rehabilitation Unit, Royal Brompton and Harefield NHS 
      Foundation Trust, Harefield, UK.
FAU - Wynne, Stephanie C
AU  - Wynne SC
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
FAU - George, Peter M
AU  - George PM
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
AD  - Interstitial Lung Disease Unit, Royal Brompton and Harefield NHS Foundation 
      Trust, London, UK.
FAU - Man, William D-C
AU  - Man WD
AD  - Harefield Pulmonary Rehabilitation and Muscle Research Laboratory, Royal Brompton 
      and Harefield NHS Foundation Trust, Harefield, UK.
AD  - Harefield Pulmonary Rehabilitation Unit, Royal Brompton and Harefield NHS 
      Foundation Trust, Harefield, UK.
AD  - National Heart and Lung Institute, Imperial College London, London, UK.
LA  - eng
GR  - CDF-2017-10-009/DH_/Department of Health/United Kingdom
GR  - DRF-2014-07-089/DH_/Department of Health/United Kingdom
GR  - PB-PG-0816-20022/DH_/Department of Health/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190905
PL  - England
TA  - Eur Respir J
JT  - The European respiratory journal
JID - 8803460
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Lung Diseases, Interstitial/*diagnosis/*rehabilitation
MH  - Male
MH  - Middle Aged
MH  - *Minimal Clinically Important Difference
MH  - Prospective Studies
MH  - *Quality of Life
MH  - ROC Curve
MH  - *Surveys and Questionnaires
MH  - Walk Test
COIS- Conflict of interest: C.M. Nolan has nothing to disclose. Conflict of interest: 
      S.S. Birring reports fees paid to King's College Hospital for use of KBILD from 
      Roche, Boehringer Ingelheim and Galapagos, outside the submitted work. Conflict 
      of interest: M. Maddocks reports grants (CDF-2017-10-009 and HSDR 16/02/18) from 
      NIHR, outside the submitted work. Conflict of interest: T.M. Maher has, via his 
      institution, received industry-academic funding from GlaxoSmithKline R&D and UCB, 
      and has received consultancy or speakers fees from Apellis, AstraZeneca, aTyr 
      Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Celgene, Galapagos, 
      GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Samumed and UCB. Conflict 
      of interest: S. Patel has nothing to disclose. Conflict of interest: R.E. Barker 
      has nothing to disclose. Conflict of interest: S.E. Jones has nothing to 
      disclose. Conflict of interest: J.A. Walsh has nothing to disclose. Conflict of 
      interest: S.C. Wynne has nothing to disclose. Conflict of interest: P.M. George 
      reports personal fees for lecturing and nonfinancial support for meeting 
      attendance from Boehringer Ingelheim and Roche Pharmaceuticals, personal fees for 
      lecturing from Teva, outside the submitted work. Conflict of interest: W.D-C. Man 
      reports grants from National Institute for Health Research, during the conduct of 
      the study; grants from Pfizer, nonfinancial support from GlaxoSmithKline, 
      personal fees from Mundipharma and Novartis, outside the submitted work.
EDAT- 2019/06/22 06:00
MHDA- 2020/07/16 06:00
CRDT- 2019/06/22 06:00
PHST- 2019/02/08 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/06/22 06:00 [pubmed]
PHST- 2020/07/16 06:00 [medline]
PHST- 2019/06/22 06:00 [entrez]
AID - 13993003.00281-2019 [pii]
AID - 10.1183/13993003.00281-2019 [doi]
PST - epublish
SO  - Eur Respir J. 2019 Sep 5;54(3):1900281. doi: 10.1183/13993003.00281-2019. Print 
      2019 Sep.